Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 2Recurrence 1Neoplasms 1Neoplasm Metastasis 1Gallbladder Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 20Fluorouracil 14Cisplatin 10Capecitabine 10Leucovorin 8durvalumab 6Oxaliplatin 6Erlotinib Hydrochloride 4Sorafenib 3Radiotherapy 3trifluridine tipiracil drug combination 2trametinib 2regorafenib 2pembrolizumab 2olaparib 2ceralasertib 2Specimen Handling 2Radiosurgery 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Magnetic Resonance Spectroscopy 2Lapatinib 2Irinotecan 2Filgrastim 2AZD 6244 2zimberelimab 1tremelimumab 1titanium silicide 1tislelizumab 1tegafur-gimeracil-oteracil 1seribantumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bile Duct Neoplasms × galactomannan × Clear all
NCT00386516 2017-08-01

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

Galectin Therapeutics Inc.

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Gallbladder Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡